

References

I-9026

1. Skysona Prescribing Information. Bluebird bio, Inc. September 2022.
2. Alsaleem M, Saadeh L. Adrenoleukodystrophy. [Updated 2021 Nov 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562328/>
3. Miller WP, Mantovani LF, Muzic J, Rykken JB, Gawande RS, Lund TC, Shanley RM, Raymond GV, Orchard PJ, Nascene DR. Intensity of MRI Gadolinium Enhancement in Cerebral Adrenoleukodystrophy: A Biomarker for Inflammation and Predictor of Outcome following Transplantation in Higher Risk Patients. *AJNR Am J Neuroradiol*. 2016 Feb;37(2):367-72. doi: 10.3174/ajnr.A4500. Epub 2015 Oct 1. PMID: 26427835; PMCID: PMC5177792.
4. Loes DJ, Hite S, Moser H, et al. Adrenoleukodystrophy: A Scoring Method for Brain MR Observations. *AJNR AM J Neuroradiol* 15:1761-1766, Oct 1994.
5. Kumar S, Sait H, Polipalli SK, Pradhan GS, Pruthi S, Kapoor S. Loes Score: Clinical and Radiological Profile of 22 Patients of X-Linked Adrenoleukodystrophy: Case Series from a Single Center. *Indian J Radiol Imaging*. 2021 Apr;31(2):383-390. doi: 10.1055/s-0041-1734366. Epub 2021 Jul 28. PMID: 34556923; PMCID: PMC8448211.
6. Bluebird Bio. A study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD). *ClinicalTrials.gov Identifier: NCT: 01896102*.